TG Therapeutics (TGTX) Stock: Buy, Sell, or Hold?
TGTX - TG Therapeutics, Inc.
$53.89
-1.50 (-2.71%)
âŧ
5d:
-4.97%
30d:
+8.87%
90d:
+12.15%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 02, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $55.98 · last confirmed Sep 9, 2026
Strength: 7.4/10
Get Alerted When TGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TGTX is fairly priced but lacks strong directional signals. At 4.4% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TGTX is fairly priced but lacks strong directional signals. At 4.4% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$92.38
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$57.36
6.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TGTX is currently trading at $53.89, which is considered fair relative to its 30-day fair value range of $49.28 to $55.63. From a valuation perspective, the stock is trading at a premium (Forward PE: 18.2) compared to its historical average (16.0). At these levels, the market is pricing in 4.4% annual earnings growth.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $52.11, while resistance sits at $58.47.
Market Sentiment: TGTX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $69.71 (+29.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TGTX is in a strong uptrend. Immediate support is located at $52.11, while resistance sits at $58.47.
Market Sentiment: TGTX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $69.71 (+29.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$49.28 -
$55.63
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.3%
Protect Your Profits
Holding TGTX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 29.4% below Wall St target ($69.71)
- BULLISH: Expecting earnings turnaround to 4.4% growth with 70.3% revenue growth
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$49.28 -
$55.63
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$52.11
Resistance Level
$58.47
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.18
Wall Street Target
$69.71
(+29.4%)
Revenue Growth (YoY)
70.3%
Earnings Growth (YoY)
-70.6%
Profit Margin
55.2%
Valuation Premium vs History
+4.4% premium
PE vs Historical
18.2 vs 16.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.4%
(market-implied from PE analysis)
1-Year Target
$56.26
(+4%)
2-Year Target
$58.74
(+9%)
3-Year Target
$61.32
(+14%)
3-Yr Target (if PE normalizes)
(PE: 18â16)
PE COMPRESSION
$53.98
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 212.1%)
$201.84
(+275%)
Base:
(SPY PE: 18.2, Growth: 212.1%)
$181.88
(+238%)
Bear:
(PE: 15.4, Growth: 212.1%)
$154.60
(+187%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 20.00 | Current EPS (TTM): $2.77
Bull Case
$65.22
(+21%)
Analyst growth 7.0%, PE expands to 22.0
Base Case
$59.29
(+10%)
Market implied 7.0%, PE stable at 20.0
Bear Case
$37.67
(-30%)
Severe decline -20.0%, PE contracts to 17.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 8:16 PM ET
Data refreshes hourly during market hours. Next update: 9:16 PM
Data refreshes hourly during market hours. Next update: 9:16 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
Advanced TGTX Option Strategies
Professional options setups generated by AI based on today's TGTX price and gamma walls.
